Epilepsy Research最新文献

{"title":"Epilepsy Arabic renaming to cerebroelectric disorder could minimize the stigma","authors":"Doaa A. Mekkawy ,&nbsp;Nirmeen kishk ,&nbsp;Noha T abokrysha ,&nbsp;Gihan M Ramzy ,&nbsp;Reham Mohamed Shamloul ,&nbsp;Rehab Magdy ,&nbsp;Alshimaa S. Othman ,&nbsp;Amr Mohamed Fouad ,&nbsp;Osama Yacoub ,&nbsp;Maged Abdel-Naseer ,&nbsp;Hatem S. Shehata ,&nbsp;Nevin M. Shalaby ,&nbsp;Amr Hassan ,&nbsp;Amal S. Ashour ,&nbsp;Ahmed Dahshan ,&nbsp;Mona Hussein ,&nbsp;Mohamed khodery ,&nbsp;Hazem Kamal Alhewag ,&nbsp;Dalia Abdelfatah ,&nbsp;Nesma Mounir","doi":"10.1016/j.eplepsyres.2024.107495","DOIUrl":"10.1016/j.eplepsyres.2024.107495","url":null,"abstract":"<div><h3>Background</h3><div>Naming is an important part of human communication. The precision of medical terms greatly influences the patients and their caregivers. \"Alsara’الصرع \" is the Arabic term defining epilepsy. However, it has a highly negative impact on patients, as reported by many caring physicians.</div></div><div><h3>Methods</h3><div>A multiple-choice face-to-face questionnaire was designed to assess stigma among patients with epilepsy (PwE), causes, impact on quality of life, impression of PwE about the Arabic terminology of epilepsy Alsara’, and their opinion regarding changing it to precise term \"itrab fi kahrabeit el mokh\" اضطراب في كهربية المخ” which means disturbance of the electrical brain activity. Stigma was assessed using a three-item stigma scale.The interviewed subjects were recruited from Cairo, Beni Suef, and Sohag University hospitals consecutively during a period from 15 August 2023 to 30 December 2023.</div></div><div><h3>Results</h3><div>Three hundred seventy-two PwE responded to the survey. Three hundred fifty-one (94.4 %) PwE felt a disease stigma. About 50 % of them attributed this stigma to the Arabic name of the disease. Eighty-four percent accepted changing the name Alsara’ into “itrab fi kahrabeit el mokh” and 77.2 % suspected a positive impact of this amendment on society. The occurrence of generalized tonic-clonic seizures was found to be an independent risk factor for epilepsy-associated stigma.</div></div><div><h3>Conclusion</h3><div>The Arabic nomenclature of epilepsy \"Alsara’\" is not an accurate term for epilepsy. In addition to being associated with many poor misconceptions and stigma. We hope this study will pave the way to replace it with a more appropriate and less defaming term.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"210 ","pages":"Article 107495"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Action potential-dependent α4-containing GABAA receptors contribute to epileptogenicity in focal cortical dysplasia","authors":"Yogesh Aggarwal ,&nbsp;Aparna Banerjee Dixit ,&nbsp;Manjari Tripathi ,&nbsp;Ramesh Doddamani ,&nbsp;Meher Chand Sharma ,&nbsp;P.Sarat Chandra ,&nbsp;Jyotirmoy Banerjee","doi":"10.1016/j.eplepsyres.2025.107520","DOIUrl":"10.1016/j.eplepsyres.2025.107520","url":null,"abstract":"<div><div>FCD is a developmental disorder associated with drug-resistant seizures. Alterations in GABA_A receptor-mediated activity contribute to seizures in FCD. However, the exact mechanism of altered GABAergic synaptic activity is still unclear. Previously, we showed increased GABA_A receptor α4 subunit expression in FCD. In this study, we investigated whether changes in GABA_A receptor configuration at synaptic or extrasynaptic sites contribute to enhanced GABAergic activity in the resected samples of FCD patients. Results showed increase in the frequency and amplitude of spontaneous inhibitory postsynaptic currents on treatment with gaboxadol (agonist for α4δ-containing GABA_A receptors). In the presence of tetrodotoxin (voltage-gated Na⁺ channel inhibitor), frequency and amplitude of miniature inhibitory postsynaptic currents were also increased upon treatment with gaboxadol. However, higher magnitude of change was observed in spontaneous inhibitory postsynaptic currents compared to miniature inhibitory postsynaptic currents on gaboxadol treatment, suggesting action potential-dependent α4-containing GABA_A receptor activity may influence epileptogenicity in FCD.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"210 ","pages":"Article 107520"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143241673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy and tolerability of brivaracetam in pediatric patients with focal-onset seizures and cognitive or learning comorbidities: Post hoc analysis of an open-label trial","authors":"Dimitrios Bourikas ,&nbsp;Juliane Koch ,&nbsp;Christine de la Loge ,&nbsp;Svetlana Dimova ,&nbsp;Sami Elmoufti ,&nbsp;Brian Moseley ,&nbsp;Lieven Lagae","doi":"10.1016/j.eplepsyres.2024.107482","DOIUrl":"10.1016/j.eplepsyres.2024.107482","url":null,"abstract":"<div><h3>Objective</h3><div>Efficacy, tolerability, and behavioral/executive functioning during long-term adjunctive brivaracetam treatment were assessed in pediatric patients with focal-onset seizures (FOS) with/without cognitive/learning comorbidities (CLC).</div></div><div><h3>Methods</h3><div>Post hoc analysis of a phase 3 open-label follow-up trial (N01266/NCT01364597). Patients with FOS (&lt;16 years at core trial entry; direct enrollers ≥4–&lt;17 years) received ≤5 mg/kg/day brivaracetam (≤200 mg/day). Subgroup analyses were performed for patients with and without ongoing CLC at baseline.</div></div><div><h3>Results</h3><div>Patients with CLC (84/185 [45.4 %]) had longer epilepsy duration and higher number of prior antiseizure medications. Kaplan-Meier–estimated brivaracetam retention at 1, 3, and 5 years was 75.0 %/78.2 %, 61.9 %/61.9 %, and 52.2 %/53.3 % in patients with/without CLC. Efficacy assessments (patients &gt;2 years of age) showed numerically lower median percent reduction in FOS frequency/28 days (43.8 %/74.1 % [n = 63/60]), 50 % responder rates for FOS (46.0 %/61.7 % [n = 63/60]), and ≥12-month continuous freedom from all seizures (31.7 %/55.9 % [n = 60/68 patients with ≥12 months treatment]) in patients with/without CLC. Treatment-emergent adverse events were reported in 94.0 %/95.0 % of patients with/without CLC (serious: 33.3 %/27.7 %; drug-related: 31.0 %/33.7 %). From baseline to last evaluation, most patients with/without CLC had no shift in T-score category for each Achenbach Child Behavior Checklist (CBCL) 1.5–5 syndrome (≥50.0 %/≥72.2 %), CBCL 6–18 syndrome (≥66.0 %/≥69.1 %), and Behavior Rating Inventory of Executive Function scale (≥66.7 %/≥69.0 %).</div></div><div><h3>Conclusions</h3><div>These data indicate that brivaracetam could be an efficacious and well-tolerated treatment option for pediatric patients with FOS with and without CLC. Behavior and executive functioning were generally stable or slightly improved in patients with and without CLC.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107482"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The characterization of psychosis and response to antipsychotic therapy in monogenic forms of familial focal epilepsy: A systematic review","authors":"Mark Ainsley Colijn","doi":"10.1016/j.eplepsyres.2024.107493","DOIUrl":"10.1016/j.eplepsyres.2024.107493","url":null,"abstract":"<div><div>While the genetic architecture of epilepsy is complex and presumably polygenic in many cases, pathogenic variants have increasingly been identified, and this is perhaps best exemplified by the monogenic familial focal epilepsies. Although individuals with epilepsy (particularly focal epilepsy) are at increased risk of developing psychosis, little has been written on this topic in relation to monogenic familial focal epilepsy, specifically. As such, this systematic review aimed to characterize the phenomenology of psychosis (and response to antipsychotic therapy) in affected individuals. Only eight articles were identified and minimal information with respect to psychiatric phenotyping was provided in most cases. As such, although no firm conclusions can be drawn, it is notable that none of the reports described a temporal relationship between seizure and psychosis onset; the typical convention used in epilepsy. As most reports also did not include primary psychotic disorder diagnoses, it remains unclear if the individuals’ presentations were understood to represent epileptic psychoses or schizophrenia, and to what degree (if at all) their genetic variants were thought to have contributed directly to psychosis risk. More robust case descriptions are needed to better characterize the nature of psychotic symptoms (and their response to treatment) in monogenic familial focal epilepsy.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107493"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late onset epilepsy findings in a developmental country, a report of first results","authors":"Hasan Saad Hosny,&nbsp;Mahmoud Salah Adly,&nbsp;Sarah Sherif Abdo,&nbsp;Sarah Khalil,&nbsp;Amr Mohamed Fouad","doi":"10.1016/j.eplepsyres.2024.107496","DOIUrl":"10.1016/j.eplepsyres.2024.107496","url":null,"abstract":"<div><h3>Introduction</h3><div>Older patients with Late onset epilepsy (LOE) provide a special set of difficulties for both the treating doctors and the patients.</div></div><div><h3>Objectives</h3><div>To address the characteristics and treatment outcomes of LOE in a cohort of Egyptian population at a tertiary center and to assess factors affecting seizure freedom in this age group.</div></div><div><h3>Methods</h3><div>From December 1, 1995, to November 30, 2020, we analysed all patients with newly diagnosed epilepsy above the age of 50 at Cairo University's neurology department. The term \"seizure freedom\" was used to refer to the absence of seizures or auras for at least 12 months. Patients were classified as either having achieved seizure freedom or not.</div></div><div><h3>Results</h3><div>One hundred and twenty-one patients were included. The median follow-up time was 24 months. 69.4 % attain seizure freedom. 52.1 % of our patients had symptomatic epilepsy. Among this group, 31.4 % (n = 38) had epilepsy caused by cerebrovascular disease (ischemic or hemorrhagic). Patients with epileptogenic lesions in neuroimaging, and those who are receiving ≥ 2 ASMs had significantly higher probability of not achieving seizure freedom for 12 months compared to those with normal or non-epileptogenic lesions in neuroimaging and receiving ≤ 1 ASMs with significant trends a trend toward lower seizure freedom in both.</div></div><div><h3>Conclusion</h3><div>Patients with Late- onset epilepsy have an excellent chance of achieving seizure freedom, especially those controlled on 1 ASM and those with normal neuroimaging.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107496"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma proteomics in epilepsy: Network-based identification of proteins associated with seizures","authors":"Saman Hosseini Ashtiani ,&nbsp;Sarah Akel ,&nbsp;Evelin Berger ,&nbsp;Johan Zelano","doi":"10.1016/j.eplepsyres.2024.107480","DOIUrl":"10.1016/j.eplepsyres.2024.107480","url":null,"abstract":"<div><h3>Purpose</h3><div>Identification of potential biomarkers of seizures.</div></div><div><h3>Methods</h3><div>In this exploratory study, we quantified plasma protein intensities in 15 patients with recent seizures compared to 15 patients with long-standing seizure freedom. Using TMT-based proteomics we found fifty-one differentially expressed proteins.</div></div><div><h3>Results</h3><div>Network analyses including co-expression networks and protein-protein interaction networks, using the STRING database, followed by network centrality and modularity analyses revealed 22 protein modules, with one module showing a significant association with seizures. The protein-protein interaction network centered around this module identified a subnetwork of 125 proteins, grouped into four clusters. Notably, one cluster (mainly enriching inflammatory pathways and Gene Ontology terms) demonstrated the highest enrichment of known epilepsy-related genes.</div></div><div><h3>Conclusion</h3><div>Overall, our network-based approach identified a protein module linked with seizures. The module contained known markers of epilepsy and inflammation. The results also demonstrate the potential of network analysis in discovering new biomarkers for improved epilepsy management.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107480"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between disease self-management and internalized stigmatization in individuals with epilepsy: A sample in eastern Turkey","authors":"Eda Ay ,&nbsp;Emrah Ay ,&nbsp;Nuray Bingol","doi":"10.1016/j.eplepsyres.2024.107497","DOIUrl":"10.1016/j.eplepsyres.2024.107497","url":null,"abstract":"<div><h3>Background</h3><div>Epilepsy is often misunderstood, leading to fear, stigmatization of patients and the risk of social discrimination. For some patients, social stigma can be an even bigger problem than epilepsy itself.</div></div><div><h3>Aim</h3><div>This study examined the relationship between self-management and internalized stigma levels in individuals diagnosed with epilepsy.</div></div><div><h3>Methods</h3><div>This descriptive and cross-sectional study was conducted in the Neurology Outpatient Clinic of a Training and Research Hospital and 128 epilepsy patients were included in the sample based on various inclusion criteria such as having a diagnosis of epilepsy for at least six months, being over the age of 18, not having any psychiatric disorder that would prevent reading and comprehension.The Sociodemographic Data Form, Internalized Stigma in Epilepsy Scale, and Epilepsy Self-Management Scale were used to collect the data.</div></div><div><h3>Results</h3><div>The mean age at disease onset was 19.5 ± 11.7 years. In terms of the demographics of the patients, 55.5 % were female, 46 % were aged 18–22 years, 53.9 % were single, 30 % were at least university graduates, 85.2 % had income equal to their expenses, 75.8 % had a seizure frequency of more than one per year, 58.6 % had generalized onset seizures, and 73.4 % used one drug. The patients’ Self-Management Scale total score was 111.01 ± 13.22, and their Internalized Stigma Scale total score was 49.9 ± 12.9. The correlation analysis indicated a high significant negative correlation between the Self-Management Scale total score and the Internalized Stigma Scale total score (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The patients’ self-management levels were above average, and their internalized stigma levels were moderate. The patients were most stigmatized in the areas of isolation and discrimination. Generally, as the self-management skills of patients increased, their internalized stigma levels decreased. In this context, it is recommended that intervention studies be conducted to increase the self-management levels and reduce stigma for individuals diagnosed with epilepsy.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107497"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epilepsy core outcome set for effectiveness trials (EPSET): A systematic review of outcomes measured in registered phase III and IV clinical trials for adults with epilepsy","authors":"James W. Mitchell ,&nbsp;Rachel Batchelor ,&nbsp;Guleed Adan ,&nbsp;Adam Noble ,&nbsp;Paula R. Williamson ,&nbsp;Tony Marson","doi":"10.1016/j.eplepsyres.2024.107481","DOIUrl":"10.1016/j.eplepsyres.2024.107481","url":null,"abstract":"<div><div>At present, little is known about the outcomes measured in studies assessing the effectiveness of treatments for adults with epilepsy. As part of a wider project developing a Core Outcome Set for clinical trials for adults with epilepsy, we summarised the current outcomes and measurement instruments used in completed phase III and IV clinical trials registered in the clinicaltrials.gov and International Standard Randomised Controlled Trial Number (ISRCTN) databases. Of the reviewed studies 104 were deemed eligible. The outcomes that were measured were recorded, and trial registry entries cross referenced against associated peer review publications. In total, 374 unique granular outcome terms were identified, which grouped into 45 outcome concepts across the following domains: seizures, cognitive/behavioural/psychiatric, sleep, general symptom, functional status / disability, emotional functioning, social functioning, delivery of care, life impact, trial processes, side effects / adverse events, pregnancy / offspring, and death. We identified evidence of outcome measurement heterogeneity, with just 10/45 outcome concepts measured in more than half of the identified studies. This association remained when assessing studies grouped by epilepsy chronicity (newly diagnosed vs. chronic/treatment refractory) and epilepsy classification (focal vs. other). These findings highlight the need for a Core Outcome Set for interventional studies for adults with epilepsy to improve consistency of outcome measurement and reporting.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107481"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and tolerability of cenobamate: A single center experience","authors":"Christopher Saouda,&nbsp;Omar Nofal,&nbsp;Yamane Makke,&nbsp;Alexandra Eid,&nbsp;Victoria Vinarsky,&nbsp;Helen Edelberg,&nbsp;Sean M. Lee,&nbsp;Mohamad Koubeissi","doi":"10.1016/j.eplepsyres.2024.107498","DOIUrl":"10.1016/j.eplepsyres.2024.107498","url":null,"abstract":"<div><h3>Introduction</h3><div>Medication-resistant epilepsy (MRE) is characterized by the failure of adequate trials of two antiseizure medications (ASMs). Numerous studies have shown that once two ASMs fail to control seizures, the likelihood of subsequent ASM regimens providing seizure control diminishes significantly. Recent clinical data on cenobamate (CNB) suggest it may offer higher rates of seizure freedom in MRE patients. This study aims to report real-world, single-center findings on the effectiveness and tolerability of CNB in treating MRE.</div></div><div><h3>Methods</h3><div>This retrospective study includes adult patients diagnosed with MRE and treated with CNB between 2020 and 2023 at The George Washington University (GWU). Data were collected from electronic medical records. Statistical analyses were conducted to evaluate CNB's impact on seizure control and patient outcomes.</div></div><div><h3>Results</h3><div>121 patients with medication-resistant epilepsy (MRE) were prescribed cenobamate (CNB). After exclusions, 104 patients were included in the effectiveness analysis and 111 in the tolerability analysis. Results showed that 34.6 % of patients achieved seizure freedom for at least three months, with a mean duration of seizure freedom of 11 ( ± 7.9) months.</div></div><div><h3>Significance</h3><div>CNB use in a large population of more than 100 patients demonstrated impressive anti-seizure activity with a good proportion of patients with MRE achieving seizure freedom despite having failed multiple prior ASMs.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107498"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical outcome and contributing presurgical evaluations in children with magnetic resonance imaging-negative epilepsy and periodic seizure cycles","authors":"Yoshihiko Saito ,&nbsp;Kenji Sugai ,&nbsp;Masaki Iwasaki ,&nbsp;Noriko Sato ,&nbsp;Akiyoshi Kakita ,&nbsp;Yuko Saito ,&nbsp;Taisuke Ohtsuki ,&nbsp;Masayuki Sasaki","doi":"10.1016/j.eplepsyres.2024.107492","DOIUrl":"10.1016/j.eplepsyres.2024.107492","url":null,"abstract":"<div><h3>Background</h3><div>The identification of surgical candidates is a critical issue in patients with magnetic resonance imaging (MRI)-negative drug-resistant focal epilepsy and latent accompanying resectable lesions, such as focal cortical dysplasia (FCD). Recently, periodic seizure cycles have been associated with FCD in both patients with MRI-positive and MRI-negative epilepsy. We investigated the presurgical evaluation and postsurgical outcome of patients with MRI-negative epilepsy with FCD and a history of periodic seizure cycles.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the characteristics of presurgical evaluation and postsurgical seizure outcome in 14 children with MRI-negative drug-resistant focal epilepsy and a history of periodic seizure cycles. All the patients had FCD histopathologically.</div></div><div><h3>Results</h3><div>The mean age at epilepsy surgery was 7.7 ± 4.7 years (0.7–16.1 years). Favorable postsurgical seizure outcome (ILAE classes 1–3) was obtained in 10 (71 %) patients five years after surgery. The relative risk of the complete concordance between imaging findings and resected area for five-year seizure freedom was 2.25 in positron emission tomography (PET) and 2.22 in subtraction ictal single-photon emission computed tomography co-registered to MRI (SISCOM), and 1.86 in magnetoencephalography (MEG).</div></div><div><h3>Conclusion</h3><div>All the children with MRI-negative focal epilepsy and a history of periodic seizure cycles were turned out to have FCD pathologically, and are good surgical candidates. Favorable seizure outcome can be expected in such patients when resective epilepsy surgery is planned based on presurgical evaluation with PET or SISCOM.</div></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"209 ","pages":"Article 107492"},"PeriodicalIF":2.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142757686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}